Abstract:Resumo Introdução e objetivos : O presente estudo avalia o efeito do ácido quelidónico na toxicidade cardíaca induzida pela doxorrubicina. O ácido quelidónico é um composto heterocíclico natural do esqueleto pirano encontrado nos rizomas da planta perene, celidónia (Chelidonium majus). Métodos : Ratos Wistar receberam injeção intraperitoneal de doxorrubicina (1,25 mg/kg, dose cumulativa de 20 mg/kg) quatro vezes por semana durante quatro semanas para induzir cardiotoxicidade. O tratamento com ácido quelidónico (10, 20 e 40 mg/kg por via oral durante quatro semanas) foi iniciado juntamente com a doxorrubicina. Resultados : O tratamento com ácido quelidónico reduziu o dano miocárdico e melhorou a disfunção cardíaca em ratos tratados com doxorrubicina. O tratamento com ácido quelidónico melhorou a pressão arterial, bem como restaurou a altura ST e normalizou o intervalo QTc em comparação com os únicos ratos tratados com doxorrubicina. A administração de ácido quelidónico por quatro semanas reduziu a pressão diastólica final do ventrículo esquerdo. Além disso, o tratamento com ácido quelidónico diminuiu o nível de marcadores cardíacos como creatina quinase-banda miocárdica (CK-MB), lactato desidrogenase (LDH), aspartato aminotransferase (AST) e troponina T cardíaca. A coloração com tricrómico, hematoxilina e eosina de Masson do tecido cardíaco revelou que o ácido quelidónico atenuou os efeitos deletérios da doxorrubicina e preveniu maiores danos e fibrose em ratos. Conclusão : Os achados do presente estudo confirmam que o tratamento com ácido quelidónico pode proteger o miocárdio contra a cardiotoxicidade induzida pela doxorrubicina. Introduction and objectives: The current study evaluates the effect of chelidonic acid on doxorubicin-induced cardiac toxicity. Chelidonic acid (CA) is a natural pyran-skeleton heterocyclic compound found in rhizomes of the perennial plant, celandine ( Chelidonium majus ). Methods: Wistar rats were given an intraperitoneal injection of doxorubicin (1.25 mg/kg, cumulative dose of 20 mg/kg) four times per week for a duration of four weeks to induce cardiotoxicity. CA treatment (10, 20, and 40 mg/kg orally for four weeks) was started together with doxorubicin. Results: CA treatment reduced myocardial damage and improved cardiac dysfunction in doxorubicin-treated rats. It improved blood pressure, restored ST wave height and normalized the QTc interval compared to the rats treated only with doxorubicin. Administration of CA for four weeks reduced left ventricular end-diastolic pressure. Moreover, CA treatment decreased the level of cardiac markers such as creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and cardiac troponin-T. Masson's trichrome, hematoxylin, and eosin staining of heart tissue revealed that CA attenuated the deleterious effects of doxorubicin and prevented further damage and fibrosis in rats. Conclusion: The study findings confirm that CA treatment can protect the myocardium against doxorubicin-induced cardiotoxicity.

Acetylcholine receptor agonists provide cardioprotection in doxorubicin-induced cardiotoxicity via modulating muscarinic M2 and α7 nicotinic receptor expression

Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis

m<SUP>6</SUP>A demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3

Vagus nerve stimulation exerts cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of programmed cell death pathways

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats

Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling.

Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways

Protective Effect of Beta-CasomorPhin-7 on Oxidative Stress and Inflammatory Response in Adriamycin Cardiomyopathy

Cardioprotection by Acetylcholine: A Novel Mechanism Via Mitochondrial Biogenesis and Function Involving the PGC‐1α Pathway

Cardioprotective effect of chelidonic acid against doxorubicin-induced cardiac toxicity in rats

Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats

Acetylcholine attenuates hypoxia/ reoxygenation-induced mitochondrial and cytosolic ROS formation in H9c2 cells via M2 acetylcholine receptor.

Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats

The Role of Muscarinic Receptors in the Beneficial Effects of Adenosine Against Myocardial Reperfusion Injury in Rats.

Protosappanin A Protects DOX-Induced Myocardial Injury and Cardiac Dysfunction by Targeting ACSL4/FTH1 Axis-Dependent Ferroptosis

Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity

Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats

Mitochonic acid 5 rescues cardiomyocytes from doxorubicin-induced toxicity via repressing the TNF-α/NF-κB/NLRP3-mediated pyroptosis